Skip to main content
MyDeficiencies

Levomilnacipran

SNRI, norepinephrine-preferring subtype; label Ki 11 nM (5-HT transporter) vs 91 nM (NE transporter), reuptake-inhibition IC50 16-19 nM (5-HT) vs 11 nM (NE); the more potent enantiomer of racemic milnacipran

Also sold as Fetzima.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Levomilnacipran has no classical absorption-interference, cofactor-antagonism, or enzyme-induction mechanism against any nutrient identified in this review, and its own label states plainly that it "did not inhibit monoamine oxidase (MAO)" and "is not an inhibitor of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1." Levomilnacipran "undergoes desethylation to form desethyl levomilnacipran and hydroxylation to form p-hydroxy-levomilnacipran," with desethylation "catalyzed primarily by CYP3A4 with minor contribution by CYP2C8, 2C19, 2D6, and 2J2," but the drug is eliminated primarily unchanged: "approximately 58% of the dose is excreted in urine as unchanged levomilnacipran," with the N-desethyl metabolite accounting for a further 18%. Plasma protein binding is low (22% over 10 to 1000 ng/mL) and levomilnacipran is "a weak substrate of P-gp." None of this PK profile implies chelation, gastric-pH change, bile-acid sequestration, or a named-transporter absorption-interference mechanism (Step 2A), nor accelerated catabolism of a co-administered nutrient (Step 2B), since levomilnacipran itself induces no major CYP enzyme in the sections reviewed. The one labeled mechanism this review carried forward is dilutional/hormonal (Step 2F): the label states "hyponatremia has occurred as a result of treatment with SSRIs and SNRIs" and "in many cases, hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)," but the very same sentence discloses that "no adverse events of hyponatremia were reported for FETZIMA-treated patients in the clinical studies" reviewed for approval, a materially weaker starting position than several other SNRIs in this series. Separately, the label's own Section 12.2 pharmacodynamics data is the primary source for this drug's defining pharmacological claim: levomilnacipran "binds with high affinity to the human serotonin (5-HT) and norepinephrine (NE) transporters (Ki = 11 and 91 nM, respectively) and potently inhibits 5-HT and NE reuptake (IC50 = 16-19 and 11 nM, respectively)." Despite SERT showing the tighter binding affinity (lower Ki), the functional reuptake-inhibition potency runs the other way, NE reuptake is inhibited at a lower (more potent) IC50 than 5-HT reuptake, a profile this dossier notes, as its own contextual observation rather than a claim made in the label itself, is commonly described in the broader pharmacology literature as distinguishing levomilnacipran from the more serotonin-weighted reuptake-inhibition profiles of venlafaxine and duloxetine.

SNRI, norepinephrine-preferring subtype; label Ki 11 nM (5-HT transporter) vs 91 nM (NE transporter), reuptake-inhibition IC50 16-19 nM (5-HT) vs 11 nM (NE); the more potent enantiomer of racemic milnacipran · ATC N06AX28 · also sold as Fetzima (Allergan and Inc. and per DailyMed labeling reviewed); no generic levomilnacipran product identified in the DailyMed listing consulted · reviewed 2026-09-30. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Levomilnacipran in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Sodium, SIADH-mediated dilutional hyponatremia

Yellow — Low

See study details

Levomilnacipran's own label documents hyponatremia as a class effect of SSRIs and SNRIs, usually via SIADH, but explicitly discloses zero hyponatremia events in FETZIMA's own clinical trials, and this review located no levomilnacipran-specific case report, so this entry is graded yellow, a mechanistic/class-level flag, not an orange- or red-level confirmed drug-specific deficit.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: The label's own statement that zero hyponatremia adverse events occurred in FETZIMA's clinical trial program is itself the most important negative finding for this entry, recorded here rather than treated as absence of evidence. This does not mean hyponatremia cannot occur with levomilnacipran (the class mechanism is real and labeled), only that no drug-specific event, in trials or in the published case-report literature searched in this review, was located.
  • At-risk subgroups: Elderly patients; patients on diuretics or otherwise volume-depleted, per the label's general SSRI/SNRI class language.

Regulatory status

FDA label, Section 5.11, verbatim: "Although no adverse events of hyponatremia were reported for FETZIMA-treated patients in the clinical studies, hyponatremia has occurred as a result of treatment with SSRIs and SNRIs. In many cases, hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)." Symptoms listed include "headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness," with severe cases including "hallucination, syncope, seizure, coma, respiratory arrest, and death." "Elderly patients may be at greater risk... patients taking diuretics or who are otherwise volume depleted can be at greater risk."

Population evidence

No levomilnacipran-specific case report, case series, or cohort study was located. A dedicated Crossref API search for "levomilnacipran SIADH hyponatremia case report" returned five results, none of which named levomilnacipran or Fetzima; all concerned hyponatremia from other causes (influenza, sarcoidosis, lung transplantation, multiple myeloma, tolvaptan management). This review's own reading of the FDA label is the only levomilnacipran-specific source located for this entry.

Mechanism

Serotonergic and noradrenergic potentiation of antidiuretic hormone (vasopressin) release and renal free-water retention, producing a dilutional fall in serum sodium (SIADH pattern), the general SSRI/SNRI class mechanism stated in the label. This is a retention/dilutional disturbance, not a dietary sodium deficiency.

Counter-evidence held on record

This entry is bounded specifically by the label's own explicit disclosure of zero drug-specific hyponatremia events in FETZIMA's trials, a materially weaker starting position than SNRIs in this series with real observed cases or case reports; the mechanism itself (SIADH, drug-class labeled) is not in doubt, only whether it has actually manifested for this specific molecule in the literature searched. This is a dilutional/retention electrolyte disturbance, not a dietary sodium deficiency, and nothing here implies sodium or fluid supplementation as a remedy; the clinical response to significant hyponatremia is fluid restriction, dose adjustment, or discontinuation under medical supervision, and increasing sodium intake around levomilnacipran use is not supported by this entry.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Not graded — disclosed evidence gap

See study details

No study of any kind testing levomilnacipran or milnacipran against mitochondrial structure, membrane integrity, electron transport, or biogenesis was located in this review, and no circulating consumer claim regarding mitochondrial effects was found to rebut as white.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. A PubMed search-listing search for "levomilnacipran mitochondria" and a separate search for "milnacipran mitochondria" each returned "No results were found" (meta-log_resultcount 0). A Crossref API search for "levomilnacipran mitochondria" surfaced only general prescribing-reference works (a Psychopharmacology Institute guide, two editions of Cambridge University Press's Prescriber's Guide, and Essential Neuropharmacology), none testing a mitochondrial endpoint. A dedicated repair pass re-ran this category with a fresh, dedicated tool allowance. A Crossref search for "levomilnacipran mitochondrial ATP" again returned only unrelated ATP-synthase and mitochondrial-pathology reference works alongside levomilnacipran prescribing guides, no overlap between the two. A separate Crossref search for "milnacipran mitochondrial biogenesis electron transport chain" returned six results, none naming milnacipran (a Drosophila electron-transport-chain paper and an unrelated cryo-EM dataset). The Europe PMC REST API returned a working response for "milnacipran AND mitochondria" (hitCount 80), but on inspection the results were fibromyalgia, pain, and unrelated oncology/neurology literature returned by relevance ranking rather than a true co-occurrence of milnacipran and mitochondrial endpoints in the same source; no result tested milnacipran against a mitochondrial outcome. New in this repair pass, the Savella (milnacipran) FDA label itself was directly fetched from DailyMed (setid 16a4a314-f97e-4e91-95e9-576a3773d284) and searched in full text for "mitochondria" or "mitochondrial": zero mentions in any section, including Adverse Reactions and Postmarketing Experience.

Channels tried

Original review: PubMed search-listing pages (both drug names) and the Crossref API (both drug names); Europe PMC and Semantic Scholar unreachable throughout. Repair pass, with a fresh dedicated tool allowance: WebSearch was attempted first but the session-wide search budget was already exhausted (200 of 200) at the moment this repair pass began, so WebSearch again contributed nothing, consistent with the environment-level constraint disclosed for this task. WebFetch was then run against PubMed (two fresh queries, both returned HTTP 429 on every attempt), Crossref (two fresh queries, both succeeded), Europe PMC (one fresh query succeeded, returned a broad, non-specific hit set; a follow-up fielded query returned HTTP 429), Semantic Scholar Graph API (two attempts, both HTTP 429), and OpenAlex (one attempt HTTP 429, a retry HTTP 503). The Savella FDA label was fetched directly from DailyMed as a new Tier A source-check.

Genuine gap vs. tooling-limited

This reads as a genuine literature gap, now on stronger footing than the original review: PubMed and Crossref again returned clean zeros across both drug names and several new phrasings, Europe PMC's one successful fresh query surfaced nothing on point despite a large, broad result set, and the milnacipran product label itself, checked directly for the first time in this repair pass, contains no mitochondrial language at all. Europe PMC, Semantic Scholar, and OpenAlex remained substantially blocked in this repair pass despite a dedicated, non-shared tool budget, matching the disclosed possibility that some of this blocking is an organization-level policy denial rather than a session-specific rate limit; a future revision with genuine access to those three channels could still change this conclusion, and that residual possibility is disclosed rather than closed off.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, enantiomer/class extrapolation from milnacipran, one human null result and one animal protective-direction signal

Yellow — Low

See study details

No study located in this review tested levomilnacipran itself against any oxidative-stress marker; this entry is carried forward at yellow strictly as a disclosed extrapolation from two real, milnacipran-specific studies, a human trial finding no significant change in oxidative stress biomarkers despite clinical response, and a rat inflammation model finding an increase in total antioxidant capacity.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: The Gupta 2023 human MDD trial is itself the key negative finding for this entry: a genuine, drug-class (milnacipran), human, prospective measurement of oxidative stress biomarkers that found no significant change despite a substantial clinical antidepressant response, recorded here as counter-evidence rather than omitted. No human oxidative-stress study of levomilnacipran itself, and no study of any kind directly comparing levomilnacipran against milnacipran on this endpoint, was located in this review.
  • At-risk subgroups: Cannot be determined; no levomilnacipran-specific data located, and the two milnacipran studies used different populations (human MDD patients versus rat inflammation model) not directly comparable to each other.

Regulatory status

Not addressed in the FETZIMA label sections reviewed.

Population evidence

Gupta R, Ghosh R, Bhatia MS, Tripathi AK, Gupta LK, "Effect of milnacipran on brain-derived neurotrophic factor and oxidative stress biomarkers in patients of major depressive disorder," Acta Neurobiologiae Experimentalis 2023;83(1):57-62, DOI 10.55782/ane-2023-006, confirmed via the Crossref API with abstract text retrieved. Human, n=30 MDD patients, milnacipran 50 to 100 mg daily for 12 weeks (drug-specific for milnacipran, Tier A/B for a hypothetical milnacipran dossier, Tier C class/enantiomer extrapolation for levomilnacipran since levomilnacipran itself was not administered): depression severity fell from 17.8±1.7 to 8.9±3.1, responders showed elevated plasma BDNF, but the study "found no significant changes in oxidative stress parameters" measured as malondialdehyde, glutathione-S-transferase, and glutathione reductase. Haddadi R, Rashtiani R, "Anti-inflammatory and anti-hyperalgesic effects of milnacipran in inflamed rats: involvement of myeloperoxidase activity, cytokines and oxidative/nitrosative stress," Inflammopharmacology 2020, confirmed via PubMed search-listing with abstract-level summary. Rat, milnacipran 10, 20, and 40 mg/kg tested in an inflammation model; milnacipran "significantly augmented" total antioxidant capacity (TAC) status, a protective-direction signal, alongside effects on myeloperoxidase activity and cytokines.

Mechanism

Not established as a single unified pathway across the two studies; neither isolated a direct, cell-free antioxidant chemistry of the milnacipran or levomilnacipran molecule itself. Both are consistent with an indirect, inflammation- or mood-state-mediated modulation of oxidative burden rather than a demonstrated direct antioxidant or pro-oxidant action.

Counter-evidence held on record

The two milnacipran sources point in different directions, a human null result in the most clinically relevant population (depression) and a protective-direction animal signal in an unrelated inflammation model, and neither administered levomilnacipran itself; this entry should be read as "milnacipran's own oxidative-stress evidence is thin and mixed," not as "levomilnacipran affects oxidative stress," a claim this review found no direct support for. No antioxidant-supplement recommendation (vitamin C, vitamin E, N-acetylcysteine, or similar) follows from this entry in either direction.

  • Gupta R, Ghosh R, Bhatia MS, Tripathi AK, Gupta LK. Effect of milnacipran on brain-derived neurotrophic factor and oxidative stress biomarkers in patients of major depressive disorder. — Human, n=30 MDD patients, milnacipran 50-100 mg/day, 12 weeks (Tier A/B for milnacipran; Tier C enantiomer/class extrapolation for levomilnacipran). Confirmed via the Crossref API with abstract text retrieved. Primary source for the Oxidative stress entry's human null finding (no significant change in malondialdehyde, glutathione-S-transferase, glutathione reductase) and BDNF increase in responders.Full text was not independently opened during this review; used at Crossref abstract-summary level only.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No study of any kind testing levomilnacipran or milnacipran against copper status, ceruloplasmin, or a copper-dependent enzyme was located in this review, including a broader SNRI-class search, and no circulating consumer claim regarding copper was found to rebut as white.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. A PubMed search-listing search for "milnacipran copper" returned "No results were found." A Crossref API search for "levomilnacipran copper zinc" returned zero relevant results (metallurgy and prescribing-reference works only, no biological content). A further, broader Crossref search for "venlafaxine duloxetine copper superoxide dismutase antidepressant," attempted specifically to test whether a cross-molecule SNRI-class extrapolation was available (as was used for this drug's Oxidative stress entry via the milnacipran enantiomer relationship), returned zero results connecting any antidepressant to copper-zinc superoxide dismutase. A dedicated repair pass re-ran this category. A fresh PubMed search-listing query for "milnacipran copper" was repeated and again returned "No results were found," confirming the original result rather than merely repeating it unverified. A fresh Crossref search for "milnacipran trace element zinc manganese" returned six results (biological trace-element papers on atherosclerosis, placental superoxide dismutase, brain mineral content, and pharmacology-reference "Zinc - Trace Element" entries), none naming milnacipran. New in this repair pass, the Savella (milnacipran) FDA label was directly fetched and searched in full text for "copper": zero mentions in any section.

Channels tried

Original review: PubMed and Crossref, at the levomilnacipran level, the milnacipran level, and a broader cross-molecule SNRI-class level; Europe PMC, Semantic Scholar, and OpenAlex unreachable. Repair pass, with a fresh dedicated tool allowance: WebSearch again contributed nothing, since the session-wide search budget was already exhausted (200 of 200) before this repair pass began. WebFetch succeeded on a repeat PubMed query and a fresh Crossref query; a further Crossref attempt and a Europe PMC attempt for this category each returned HTTP 429 and could not be completed. The Savella FDA label was fetched directly from DailyMed as a new Tier A source-check.

Genuine gap vs. tooling-limited

This is disclosed as a genuine gap at the levomilnacipran and milnacipran level, now checked across three independent channels (PubMed, Crossref, and the milnacipran product label itself) with a consistent clean zero, plus the earlier broader cross-molecule SNRI-class attempt that also returned zero. Europe PMC, Semantic Scholar, and OpenAlex remained substantially blocked in this repair pass despite a dedicated, non-shared tool budget, consistent with the disclosed possibility of an organization-level policy denial rather than a purely session-specific limit; a future revision with genuine access to those channels could still surface class-level evidence this review could not reach.

Iron

Not graded — disclosed evidence gap

See study details

No study of any kind associating levomilnacipran or milnacipran with iron status, periodic limb movements, or restless-legs-type symptoms was located in this review, and no circulating consumer claim regarding iron was found to rebut as white.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. A PubMed search combining "levomilnacipran" and "iron" and "deficiency" returned zero results; a Crossref API search using the same terms surfaced only unrelated pediatric and agricultural iron-deficiency content, with one irrelevant levomilnacipran prescribing guide appearing separately and flagged by the fetch itself as unrelated to iron deficiency. A PubMed search for "milnacipran iron deficiency" returned "No results were found." A Crossref API search for "milnacipran restless legs periodic limb movement" (the mechanism pathway used for Iron entries elsewhere in this series, via other SNRIs' documented periodic-limb-movement associations) returned zero relevant results; all five results returned were general restless-legs-syndrome reference works with no antidepressant, let alone milnacipran, named. A dedicated repair pass re-ran this category. A fresh PubMed query for "milnacipran iron" was repeated and again returned "No results were found." A fresh Crossref query for "levomilnacipran hemoglobin anemia" returned six results, all hemoglobinopathy and sickle-cell-anemia literature with no antidepressant named. New in this repair pass, the Savella (milnacipran) FDA label was directly fetched and searched in full text for "iron," "anemia," and "hematocrit": zero mentions in any section.

Channels tried

Original review: PubMed and Crossref, at both the levomilnacipran and milnacipran level, testing both a direct iron-status query and the restless-legs/periodic-limb-movement pathway. Repair pass, with a fresh dedicated tool allowance: WebSearch again contributed nothing, since the session-wide search budget was already exhausted (200 of 200) before this repair pass began. WebFetch succeeded on a repeat PubMed query and a fresh Crossref query; further Crossref, Europe PMC, Semantic Scholar, and OpenAlex attempts for this category each returned HTTP 429 or HTTP 503 and could not be completed. The Savella FDA label was fetched directly from DailyMed as a new Tier A source-check.

Genuine gap vs. tooling-limited

This reads as a genuine gap: unlike some other SNRIs in this series, no periodic-limb-movement or restless-legs association was located for milnacipran itself in the channels this review could reach, so even the weaker, multi-step class-extrapolation chain used for those other drugs' Iron entries has no starting point here, and the milnacipran product label itself, checked directly in this repair pass, contains no iron, anemia, or hematocrit language at all. Europe PMC, Semantic Scholar, and OpenAlex remained substantially blocked in this repair pass despite a dedicated, non-shared tool budget, consistent with the disclosed possibility of an organization-level policy denial; a future revision with genuine access to those channels could still change this.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, drug-specific gastrointestinal motility signal, no direct microbiome-composition study located at any level

Yellow — Low

See study details

Levomilnacipran's own label documents substantial, dose-relevant gastrointestinal adverse-reaction rates, nausea, constipation, and vomiting, a real, drug-specific and mechanistically plausible but indirect pathway to microbiome disruption, while no direct microbiome-composition study of levomilnacipran or milnacipran was located in this review despite a genuine search effort.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No microbiome-composition study, positive or negative, was located for levomilnacipran or milnacipran at any tier in this review.
  • At-risk subgroups: Not defined beyond the general, dose-related pattern in the label's adverse-reaction tables (higher GI adverse-event rates at higher FETZIMA doses).

Regulatory status

FDA label, Section 6.1, Table 3, verbatim rates (FETZIMA vs placebo): nausea 17% vs 6%, constipation 9% vs 3%, vomiting 5% vs 1%. The label's own summary states "the most commonly observed adverse events in FETZIMA-treated MDD patients in placebo-controlled studies... were: nausea, constipation, hyperhidrosis, heart rate increased, erectile dysfunction, tachycardia, vomiting, and palpitations."

Population evidence

The label's own clinical-trial adverse-reaction tables are the drug-specific Tier A source for the motility signal. No direct microbiome-composition, diversity, or functional-marker study of levomilnacipran was located; a Crossref API search for "levomilnacipran gut microbiome microbiota" could not be completed in this review after repeated rate-limiting (disclosed in Sources). A Crossref API search for "milnacipran antimicrobial gut bacteria" returned zero relevant results (five results returned, none testing milnacipran's antimicrobial activity or composition effects on gut bacteria).

Mechanism

Serotonin is a major enteric neurotransmitter, and SSRI/SNRI-class serotonin-reuptake inhibition is a well-established general mechanism for altered gastrointestinal motility (nausea, altered transit, constipation, or diarrhea depending on the individual and dose); levomilnacipran's substantially elevated nausea, constipation, and vomiting rates relative to placebo are consistent with this general class mechanism, though the label does not test or report a direct microbiome-composition endpoint, so the link to actual microbial composition change is inferred, not measured, in this review.

Counter-evidence held on record

This entry deliberately separates what is actually drug-specific for levomilnacipran (the labeled GI adverse-reaction incidence) from what remains unconfirmed (an actual microbiome-composition effect); a reader should not treat the nausea/constipation/vomiting rates as proof of a microbiome effect, since no study located in this review connected the two directly for either levomilnacipran or milnacipran. No probiotic or microbiome-support supplement recommendation follows from this entry.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery / utilization

Not graded — disclosed evidence gap

See study details

Levomilnacipran's own label and most recent postmarketing data contain no hematologic adverse reaction of any kind, and no study associating levomilnacipran or milnacipran with anemia, hemoglobin, or hematocrit was located in this review; no circulating consumer claim regarding oxygen delivery or anemia was found to rebut as white.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. The most recent DailyMed labeling's Section 6.2 Postmarketing Experience lists only two terms across the drug's entire market history, "Takotsubo cardiomyopathy" and "Anosmia, Hyposmia," neither hematologic. A PubMed search for "levomilnacipran anemia" returned "No results were found." A Crossref API search for "milnacipran anemia hemoglobin hematologic" returned zero relevant results, surfacing only unrelated sickle-cell and thalassemia hematology literature with no antidepressant named. This review deliberately notes, and does not grade, the label's own heart-rate and blood-pressure findings (a labeled mean heart-rate increase of 7.4 bpm and blood-pressure increases of 3.0/3.2 mmHg) separately in the Pharmacokinetic basis and Monitoring panel, since per Hard Rule 2 these are levomilnacipran's own intended noradrenergic pharmacodynamic actions, not a nutrient-style oxygen-delivery deficiency, and must never be filed as one. A dedicated repair pass re-ran this category. A fresh Crossref search for "levomilnacipran hemoglobin anemia" returned zero relevant results (sickle-cell and hemoglobinopathy literature only). A further fresh Crossref search for "milnacipran tissue oxygenation oxygen delivery" returned six results, all general critical-care or physiology literature on oxygen delivery and tissue oxygenation, none naming milnacipran or any antidepressant. New in this repair pass, the Savella (milnacipran) FDA label was directly fetched and searched in full text for "oxygen," "hemoglobin," "hematocrit," and "anemia": zero mentions in any section, mirroring the levomilnacipran label's own clean postmarketing record for this category.

Channels tried

Original review: PubMed and Crossref, at both the levomilnacipran and milnacipran level, plus a full read of the FDA label's Section 6.1 adverse-reaction tables and the DailyMed Section 6.2 Postmarketing Experience listing. Repair pass, with a fresh dedicated tool allowance: WebSearch again contributed nothing, since the session-wide search budget was already exhausted (200 of 200) before this repair pass began. WebFetch succeeded on two fresh Crossref queries; Europe PMC, Semantic Scholar, and OpenAlex attempts for this category each returned HTTP 429 or HTTP 503 and could not be completed. The Savella FDA label was fetched directly from DailyMed as a new Tier A source-check.

Genuine gap vs. tooling-limited

The absence of any hematologic signal in levomilnacipran's own label and postmarketing data, despite the drug being on the US market since 2013, is itself a genuine null finding, recorded here rather than silently treated as insufficient data, and this repair pass adds a matching clean result from the milnacipran product label itself, checked directly for the first time. This review cannot determine whether the absence reflects a true pharmacological difference from other SNRIs with labeled hematologic effects, a smaller postmarketing exposure base for a less-prescribed, newer drug, or reporting/surveillance variance, and does not assert any one of those explanations as established. Europe PMC, Semantic Scholar, and OpenAlex remained substantially blocked in this repair pass despite a dedicated, non-shared tool budget, consistent with the disclosed possibility of an organization-level policy denial; a future revision with genuine access to those channels could still change this.

ATP production

Not graded — disclosed evidence gap

See study details

No study of any kind measured ATP yield, cellular respiration, or energy-substrate balance after levomilnacipran or milnacipran administration in this review, and no circulating consumer claim regarding energy or ATP was found to rebut as white.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The dual condition for ungraded is met: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. A Crossref API search for "milnacipran ATP energy metabolism mitochondrial" returned five results; four were generic mitochondrial-physiology or ATP-synthesis reference works unrelated to any antidepressant, and the fifth, Li F, Chin C, Wangsa J, Ho J, "Excretion and Metabolism of Milnacipran in Humans after Oral Administration of Milnacipran Hydrochloride," Drug Metabolism and Disposition 2012, DOI 10.1124/dmd.112.045120, was a pharmacokinetic excretion study, not an energy-metabolism or ATP study, despite matching the search terms. A direct "levomilnacipran ATP" query at the OpenAlex API could not be completed in the original review after repeated rate-limiting. This category's original tooling caveat, that the planned direct PubMed and OpenAlex follow-up was cut off before completing, is addressed in this dedicated repair pass. A fresh Crossref search for "levomilnacipran ATP energy metabolism" returned six results, all generic ATP-biochemistry or energy-metabolism reference works (a Cambridge University Press cellular-energetics chapter, a heart-metabolism book chapter, a ruminant-energetics chapter, and similar), none naming levomilnacipran. The planned PubMed follow-up was re-attempted with two fresh queries ("milnacipran ATP production" and "milnacipran cellular energy") and both returned HTTP 429 on every attempt in this repair pass. The planned OpenAlex follow-up was re-attempted twice and returned HTTP 429 then HTTP 503, still unreachable. New in this repair pass, the Savella (milnacipran) FDA label was directly fetched and searched in full text for "ATP" and "energy metabolism": zero mentions in any section.

Channels tried

Original review: the Crossref API, at both the levomilnacipran and milnacipran level; a PubMed attempt and an OpenAlex attempt were both blocked before returning results. Repair pass, with a fresh dedicated tool allowance: WebSearch again contributed nothing, since the session-wide search budget was already exhausted (200 of 200) before this repair pass began, matching the disclosed environment-level constraint for this task. WebFetch succeeded on a fresh Crossref query; the planned PubMed and OpenAlex follow-up queries were both re-attempted as promised in the original review and both failed again (PubMed HTTP 429 twice; OpenAlex HTTP 429 then HTTP 503), and a Europe PMC fielded query for this category also returned HTTP 429. The Savella FDA label was fetched directly from DailyMed as a new Tier A source-check, succeeding where the bibliographic APIs could not.

Genuine gap vs. tooling-limited

This category's tooling-limited caveat from the original review has now been genuinely retested with a dedicated, non-shared tool budget, and the PubMed and OpenAlex follow-up queries that were cut off before are confirmed still blocked rather than merely unattempted, consistent with the disclosed possibility that this reflects an organization-level policy denial rather than a session-specific rate limit that a larger budget would clear. Weighed against that, two independent channels did succeed in this repair pass, a fresh Crossref query and a first-time direct read of the milnacipran product label, and both returned a clean zero, which moves this entry's balance further toward a genuine literature gap than the original review could establish, though PubMed and OpenAlex direct-drug-name searches for ATP-specific terms remain a disclosed, unresolved gap in coverage that a future revision should re-attempt.

  • Crossref API, query.bibliographic "milnacipran ATP energy metabolism mitochondrial." — Directly opened. Four of five results were generic mitochondrial/ATP-physiology reference works unrelated to any antidepressant; the fifth, Li F, Chin C, Wangsa J, Ho J, "Excretion and Metabolism of Milnacipran in Humans after Oral Administration of Milnacipran Hydrochloride," Drug Metabolism and Disposition 2012, DOI 10.1124/dmd.112.045120, was a pharmacokinetic excretion study, not an ATP or energy-metabolism study.

How the body handles this medication

Metabolism (minor pathway; CYP3A4-primary desethylation, but most of the dose is never metabolized)
"Levomilnacipran undergoes desethylation to form desethyl levomilnacipran and hydroxylation to form p-hydroxy-levomilnacipran," with desethylation "catalyzed primarily by CYP3A4 with minor contribution by CYP2C8, 2C19, 2D6, and 2J2." Levomilnacipran "did not inhibit monoamine oxidase (MAO)" and "is not an inhibitor of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1."FDA, FETZIMA full prescribing information, accessdata.fda.gov, 204168s000lbl.pdf, Sections 12.3 and 7.5
Elimination (predominantly renal, and predominantly unchanged)
"Levomilnacipran and its metabolites are eliminated primarily by renal excretion. Following oral administration of 14C-levomilnacipran solution, approximately 58% of the dose is excreted in urine as unchanged levomilnacipran," with "N-desethyl levomilnacipran... the major metabolite excreted in the urine," accounting for "approximately 18% of the dose." A materially higher fraction of unchanged renal excretion than most CYP-dependent antidepressants, consistent with a limited hepatic-biotransformation burden.FDA, FETZIMA prescribing information, Section 12.3
Absorption, distribution, and food effect
Extended-release capsule; "relative bioavailability of levomilnacipran after administration of FETZIMA ER was 92% when compared to oral solution"; median Tmax 6 to 8 hours. "Levomilnacipran concentration was not significantly affected when FETZIMA was administered with food." Plasma protein binding is low, "22% over concentration range of 10 to 1000 ng/mL," with "an apparent volume of distribution of 387-473 L," indicating extensive tissue distribution. No chelation, gastric-pH-dependent, bile-acid-sequestration, or named-transporter absorption-interference mechanism (Step 2A) is identified in the label.FDA, FETZIMA prescribing information, Section 12.3
Renal and hepatic impairment dosing
Mild renal impairment (CrCl 60-89 mL/min): "dose adjustment is not recommended." Moderate impairment (CrCl 30-59 mL/min): "the maintenance dose should not exceed 80 mg once daily." Severe impairment (CrCl 15-29 mL/min): "the maintenance dose should not exceed 40 mg once daily." "FETZIMA is not recommended for patients with end stage renal disease." By contrast, "dose adjustment is not recommended in subjects with mild (Child-Pugh score of 1-6), moderate (Child-Pugh score of 7-9), or severe (Child-Pugh score of 10-13) hepatic impairment," reflecting the drug's renal-clearance-dependent, largely non-hepatic disposition.FDA, FETZIMA prescribing information, Sections 2.3 and 8.6
CYP3A4 interaction asymmetry and P-gp status
"The dose of FETZIMA should not exceed 80 mg once daily when used with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, ritonavir)," but "no dose adjustment of FETZIMA is needed when co-administered with a CYP3A4 inducer," an asymmetry consistent with CYP3A4 desethylation being only a minor clearance pathway relative to unchanged renal excretion. Levomilnacipran is described as "a weak substrate of P-gp." No mineral, antacid, or dietary-supplement interaction is documented in the sections of the label reviewed.FDA, FETZIMA prescribing information, Section 7
Dilutional/hormonal disturbance (mechanism present, but explicitly zero drug-specific events in FETZIMA's own trials; drives the Sodium entry)
"Although no adverse events of hyponatremia were reported for FETZIMA-treated patients in the clinical studies, hyponatremia has occurred as a result of treatment with SSRIs and SNRIs. In many cases, hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)." "Elderly patients may be at greater risk... patients taking diuretics or who are otherwise volume depleted can be at greater risk." This is a retention/dilutional disturbance, not a dietary depletion, and per this project's framing rule is graded on the same tier scale but never implies sodium supplementation as a remedy (see Sodium entry).FDA, FETZIMA prescribing information, Section 5.11
Noradrenergic pharmacodynamics: cardiovascular, gastrointestinal, urinary, and reproductive effects (mechanism clarification and monitoring context, not standalone nutrient entries, per Hard Rule 2)
"FETZIMA treatment was associated with a mean increase in heart rate of 7.4 beats per minute (bpm) compared to a mean decrease of 0.3 bpm in placebo-treated patients," alongside mean increases of 3.0 mmHg systolic and 3.2 mmHg diastolic blood pressure versus placebo. "Urinary hesitation occurred in 4%, 5% and 6% of FETZIMA-treated patients receiving doses of 40, 80 and 120 mg, respectively, compared to no patients in the placebo group." Erectile dysfunction (6% vs 1% placebo), ejaculation disorder (5% vs <1%), and testicular pain (4% vs <1%) were each labeled at ≥2% and at least twice the placebo rate. Nausea (17% vs 6%), constipation (9% vs 3%), and vomiting (5% vs 1%) were the most prominent gastrointestinal effects (see Gut microbiome risk entry). These are levomilnacipran's own intended or expected noradrenergic and serotonergic pharmacodynamic actions, not nutrients the drug depletes, and per Hard Rule 2 are carried into the Monitoring panel rather than graded as deficiency entries.FDA, FETZIMA prescribing information, Sections 5.3, 5.4, 5.7, and 6.1
All references used above
  1. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, search "levomilnacipran." — Confirmed ATC code N06AX28 for levomilnacipran. No DDD value was visible in the search-result page returned; the full individual code entry was not separately opened in this review. Directly opened via WebFetch.
  2. FDA. FETZIMA (levomilnacipran) extended-release capsules, full prescribing information, original approval. — FDA label (Tier A). Directly opened and read via WebFetch, across two separate fetches. Primary source for Section 12.1 mechanism of action, Section 12.2 pharmacodynamics (Ki and IC50 binding/inhibition data), Section 12.3 pharmacokinetics (metabolism, elimination, absorption, food effect, protein binding, volume of distribution), Section 2.3 renal dosing, Section 8.6 hepatic dosing, Section 7 and 7.5 drug interactions (CYP3A4, P-gp, MAOI), Section 5.3 blood pressure, Section 5.4 heart rate, Section 5.5 abnormal bleeding, Section 5.7 urinary hesitation, Section 5.10 discontinuation symptoms, Section 5.11 hyponatremia/SIADH, Section 6.1 adverse reaction tables (including sexual/reproductive and gastrointestinal rates), and Section 8 use in specific populations.
  3. DailyMed. FETZIMA (levomilnacipran hydrochloride) extended-release capsules, most recent labeling, Allergan, Inc. — FDA label (Tier A), most recent revision. Directly opened and read via WebFetch. Primary source for Section 6.2 Postmarketing Experience (Takotsubo cardiomyopathy; anosmia, hyposmia), cross-checked hematologic, electrolyte, hepatic, and metabolic adverse-reaction content against the 2013 label, and confirmed available strengths (20, 40, 80, 120 mg) and packager. No ATC code was listed directly in this document.
  4. PubMed search-listing page, query "levomilnacipran mitochondria." — Directly opened. Returned "No results were found," meta-log_resultcount 0.
  5. PubMed search-listing page, query "levomilnacipran anemia." — Directly opened. Returned "No results were found," meta-log_resultcount 0.
  6. Crossref API, query "levomilnacipran mitochondria." — Directly opened. Surfaced only general prescribing-reference works (Psychopharmacology Institute guide 2025; Cambridge University Press Prescriber's Guide 7th and 8th editions; Essential Neuropharmacology 2nd edition), none testing a mitochondrial endpoint.
  7. Crossref API, query.bibliographic "levomilnacipran iron deficiency." — Directly opened. Zero relevant results; returned pediatric iron-deficiency, agricultural iron-deficiency, and unrelated hematology-atlas content, plus one levomilnacipran prescribing guide flagged by the fetch itself as unrelated to iron deficiency.
  8. Crossref API, query.bibliographic "levomilnacipran copper zinc." — Directly opened. Zero relevant results; returned metallurgy (copper-tin, copper-zinc alloy) references and unrelated levomilnacipran prescribing guides.
  9. Crossref API, query.bibliographic "levomilnacipran anemia hemoglobin" and "levomilnacipran gut microbiome" and "levomilnacipran ATP energy."These three follow-up direct-drug-name queries could not be completed in this review; each attempt returned an HTTP 429 rate-limit response from either the WebFetch proxy or the target API and was not successfully retried within this review's time constraints, disclosed here as a tooling-limited gap rather than a completed zero-result search.
  10. Drugs.com. Fetzima side effects page. — Consumer drug-information source compiling FDA labeling. Directly opened. Source for cross-checking hyponatremia, decreased-appetite, increased-cholesterol, and thirst content, and for the circulating-claim audit (no nutrient-depletion content found; only a St. John's wort/tryptophan serotonin-syndrome interaction note).
  11. RxList. Fetzima drug page. — Consumer drug-information source. Directly opened. Reviewed for the circulating-claim audit; explicitly no mentions found of nutrient depletion, vitamin or mineral deficiencies, mitochondrial effects, oxidative stress, copper or iron metabolism, gut microbiome impacts, or ATP/cellular energy production.
  12. PubMed search-listing page, query "milnacipran oxidative stress." — Directly opened. Surfaced Gupta R et al, Acta Neurobiologiae Experimentalis 2023 (milnacipran-specific, human MDD, oxidative-stress biomarkers); Haddadi R, Rashtiani R, Inflammopharmacology 2020 (milnacipran-specific, rat inflammation model, TAC status); and an unrelated analytical-chemistry purity-testing paper, correctly excluded as not administering the compound.
  13. Gupta R, Ghosh R, Bhatia MS, Tripathi AK, Gupta LK. Effect of milnacipran on brain-derived neurotrophic factor and oxidative stress biomarkers in patients of major depressive disorder. — Human, n=30 MDD patients, milnacipran 50-100 mg/day, 12 weeks (Tier A/B for milnacipran; Tier C enantiomer/class extrapolation for levomilnacipran). Confirmed via the Crossref API with abstract text retrieved. Primary source for the Oxidative stress entry's human null finding (no significant change in malondialdehyde, glutathione-S-transferase, glutathione reductase) and BDNF increase in responders.Full text was not independently opened during this review; used at Crossref abstract-summary level only.
  14. Haddadi R, Rashtiani R. Anti-inflammatory and anti-hyperalgesic effects of milnacipran in inflamed rats: involvement of myeloperoxidase activity, cytokines and oxidative/nitrosative stress. — Rat, milnacipran 10/20/40 mg/kg, inflammation model (Tier B for milnacipran; Tier C enantiomer/class extrapolation for levomilnacipran). Confirmed via PubMed search-listing with abstract-level summary, including the verbatim finding that milnacipran "significantly augmented...TAC status."Full text was not independently opened during this review; used at title/search-listing-confirmed level only.
  15. PubMed search-listing page, query "milnacipran mitochondria," and separately "milnacipran copper," "milnacipran iron deficiency." — Directly opened for each query. Each independently confirmed to return "No results were found" with meta-log_resultcount 0.
  16. Crossref API, query.bibliographic "milnacipran periodic limb movement restless legs." — Directly opened. Zero relevant results; returned five general restless-legs-syndrome reference works, none naming milnacipran or any other antidepressant as a studied compound.
  17. Crossref API, query.bibliographic "milnacipran antimicrobial gut bacteria." — Directly opened. Zero relevant results; returned general antimicrobial-resistance and gut-bacteria bioprospecting literature, none testing milnacipran.
  18. Crossref API, query.bibliographic "milnacipran ATP energy metabolism mitochondrial." — Directly opened. Four of five results were generic mitochondrial/ATP-physiology reference works unrelated to any antidepressant; the fifth, Li F, Chin C, Wangsa J, Ho J, "Excretion and Metabolism of Milnacipran in Humans after Oral Administration of Milnacipran Hydrochloride," Drug Metabolism and Disposition 2012, DOI 10.1124/dmd.112.045120, was a pharmacokinetic excretion study, not an ATP or energy-metabolism study.
  19. Crossref API, query.bibliographic "milnacipran anemia hemoglobin hematologic." — Directly opened. Zero relevant results; returned unrelated sickle-cell anemia, thalassemia, and malarial-anemia hematology literature, none naming milnacipran or any antidepressant.
  20. Crossref API, query.bibliographic "venlafaxine duloxetine copper superoxide dismutase antidepressant." — Directly opened. Zero relevant results; returned copper-zinc superoxide dismutase protein-chemistry literature (structural/catalytic-mechanism studies), none naming any antidepressant. Attempted specifically to test a broader, cross-molecule SNRI-class extrapolation for the Copper entry, over and above the milnacipran enantiomer relationship used elsewhere in this dossier.
  21. Crossref API, query.bibliographic "levomilnacipran SIADH hyponatremia case report." — Directly opened. Zero relevant results; returned five case reports/abstracts on hyponatremia from other causes (influenza, sarcoidosis, lung transplantation, multiple myeloma, tolvaptan management), none naming levomilnacipran or Fetzima.
  22. Repair pass, 2026-09-30: DailyMed, SAVELLA (milnacipran hydrochloride) full prescribing information, Allergan, Inc. — FDA label (Tier A) for milnacipran itself, not previously fetched in the original review of this dossier. Directly opened and read via WebFetch in full and searched for "mitochondria," "mitochondrial," "copper," "iron," "anemia," "hemoglobin," "hematocrit," "ATP," and "energy metabolism": zero mentions of any of these terms in any section, including Adverse Reactions and Postmarketing Experience. Cited in each of the five ungraded category entries above as a new Tier A negative-finding source at the milnacipran level.
  23. Repair pass, 2026-09-30: DailyMed drug-listing search, query "milnacipran." — Directly opened. Used to locate the Savella setid above among 11 milnacipran-containing products listed (five generic milnacipran HCl tablet listings and six Savella listings from different repackagers).
  24. Repair pass, 2026-09-30: Crossref API, query.bibliographic "levomilnacipran mitochondrial ATP," "levomilnacipran hemoglobin anemia," "levomilnacipran ATP energy metabolism," "milnacipran trace element zinc manganese," "milnacipran mitochondrial biogenesis electron transport chain," and "milnacipran tissue oxygenation oxygen delivery." — Six fresh queries, all directly opened and succeeding. All six returned zero results connecting the target drug name to the queried category; returned works were unrelated reference literature (ATP-synthase biochemistry, hemoglobinopathy/sickle-cell literature, generic energy-metabolism textbook chapters, trace-element biology, Drosophila electron-transport-chain research, and critical-care oxygen-delivery physiology), none naming levomilnacipran or milnacipran as a studied compound. Full result lists are summarized in each corresponding ungraded entry above.
  25. Repair pass, 2026-09-30: Europe PMC REST API, query "milnacipran AND mitochondria." — Directly opened; one of very few successful Europe PMC fetches across this dossier's original review and this repair pass combined. Returned hitCount 80, but on review this reflects broad relevance-ranked matching rather than a strict co-occurrence requirement: the listed results (fibromyalgia biomarker and mechanism reviews, unrelated oncology and neuropathic-pain papers, an anesthesia narrative review) do not include any study testing milnacipran against a mitochondrial endpoint. A follow-up fielded query restricting to an explicit quoted-phrase co-occurrence returned HTTP 429 and could not be completed.
  26. Repair pass, 2026-09-30: PubMed search-listing pages, repeat queries "milnacipran copper" and "milnacipran iron," and fresh queries "milnacipran ATP mitochondrial," "milnacipran ATP production," "milnacipran cellular energy," "levomilnacipran mitochondrial" (x2), and "SNRI antidepressant mitochondrial dysfunction." — The two repeat queries succeeded and reconfirmed "No results were found" for both. The "milnacipran ATP mitochondrial" query returned a page with no results section content, read as inconclusive rather than a confirmed zero. The five remaining fresh queries each returned HTTP 429 and could not be completed in this repair pass.
  27. Repair pass, 2026-09-30: OpenAlex API, queries "milnacipran mitochondrial ATP" and "levomilnacipran" (x2); Semantic Scholar Graph API, queries "milnacipran mitochondrial ATP" and "levomilnacipran copper iron"; further Crossref and Europe PMC attempts beyond those listed above.None of these could be completed. OpenAlex returned HTTP 429 once and HTTP 503 twice; Semantic Scholar returned HTTP 429 on both attempts; the further Crossref and Europe PMC attempts each returned HTTP 429, several carrying an explicit instruction not to retry that same page. This pattern, persisting under a tool budget disclosed as dedicated to this medication's repair rather than shared with other concurrent work, is consistent with the possibility, flagged for this task, that some of this blocking is an organization-level policy denial rather than a purely session-specific rate limit.
  28. Access-limited channels, disclosed across the original review and this repair pass.Original review: this review's WebSearch tool allowance was exhausted before research on this medication began (200 of 200 calls used across this session's prior work), so all research relied on WebFetch against known URLs. Within WebFetch, the Europe PMC REST API (www.ebi.ac.uk/europepmc/webservices/rest/) and Semantic Scholar Graph API (api.semanticscholar.org) returned HTTP 429 rate-limit responses or were otherwise unreachable on effectively every attempt made in this review. The OpenAlex API (api.openalex.org) succeeded on isolated early attempts but returned HTTP 429 on every attempt made specifically for this medication's research. PubMed's search-listing pages (pubmed.ncbi.nlm.nih.gov/?term=...) and the Crossref API (api.crossref.org) were each intermittently reachable throughout the review, with HTTP 429 responses recurring, at times clearing after a one-to-two-minute wait and at times persisting across multiple such waits regardless of host or query, consistent with a session-wide rate-limit condition rather than a query-specific or host-specific block; direct bash-level curl access to these same hosts was separately and consistently refused by this environment's egress proxy for policy reasons unrelated to rate-limiting. Repair pass: WebSearch was attempted first, at this repair task's explicit instruction, and immediately reported the session-wide budget already exhausted at 200 of 200, before this repair pass issued a single query of its own, confirming this is a session-wide, not a per-subagent, allowance. WebFetch access was genuinely more productive than in the original review for Crossref (six of eight fresh queries succeeded) and produced one new working channel, a direct fetch of the Savella milnacipran FDA label, but PubMed, Europe PMC, Semantic Scholar, and OpenAlex remained substantially blocked despite this repair pass's dedicated, non-shared tool budget, several PubMed and Europe PMC responses explicitly instructing not to retry the same page even after waiting. This is consistent with the possibility, disclosed for this task, that some of this blocking reflects an organization-level policy denial that persists under a dedicated solo budget rather than a session-specific rate limit that more time or a fresh allowance would clear. Where a category above is marked ungraded or notes an incomplete follow-up query, this is the disclosed cause.